Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
29.00
-1.01 (-3.37%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $6.23M in the quarter ending March 31, 2026, a decrease of -96.07%. This brings the company's revenue in the last twelve months to $32.08M, down -83.20% year-over-year. In the year 2025, Stoke Therapeutics had annual revenue of $184.42M with 404.50% growth.
Revenue (ttm)
$32.08M
Revenue Growth
-83.20%
P/S Ratio
56.30
Revenue / Employee
$188,706
Employees
170
Market Cap
1.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.42M | 147.87M | 404.50% |
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Zai Lab | 453.28M |
| Vericel | 292.09M |
| Iovance Biotherapeutics | 285.61M |
| Zymeworks | 81.26M |
| Recursion Pharmaceuticals | 66.41M |
| Ocular Therapeutix | 52.04M |
| Nanobiotix | 38.27M |
STOK News
- 11 hours ago - Stoke Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 days ago - Stoke Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Stoke Therapeutics Transcript: AGM 2026 - Transcripts
- 11 days ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in June - Business Wire
- 21 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 4 weeks ago - Stoke Therapeutics reports Q1 EPS (79c), consensus (84c) - TheFly
- 4 weeks ago - Stoke Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Stoke Therapeutics Earnings release: Q1 2026 - Filings